^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:letrozole (Aromatase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2 Negative Breast Cancer: Invasive Breast Cancer…SYSTEMIC THERAPY FOR ER - AND/OR PR - POSITIVE RECURRENT OR STAGE IV (M1) DISEASE…HER2-Negative and Postmenopausal or Premenopausal Receiving Ovarian Ablation or Suppression…Preferred Regimens...Seletive ER-down regulator(fulvestrant, category 1)+/-non-steroidal aromatase inhibhitor (anastrozole, letrozole) (category 1)
    Secondary therapy:
    fulvestrant
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Hormone Receptor Positive Breast Cancer)
    New
    Excerpt:
    Femara is an aromatase inhibitor indicated for:...Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

    Excerpt:
    ...The number of stained cells will be compared in tissue that is hormone receptor-positive tissue to tissue that is hormone receptor negative.`...
    Trial ID:
    NCT00651976
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

    Excerpt:
    ...Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies, with hormone receptor positive and human epidermal growth factor receptor 2 negative confirmed by tumor histopathology and molecular pathology....
    Trial ID:
    NCT05744687
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

    Excerpt:
    ...- Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer...
    Trial ID:
    NCT01225172